These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 31713476

  • 1. Real-World Clinical Effectiveness and Tolerability of Hydroxychloroquine 400 Mg in Uncontrolled Type 2 Diabetes Subjects who are not Willing to Initiate Insulin Therapy (HYQ-Real-World Study).
    Gupta A.
    Curr Diabetes Rev; 2019; 15(6):510-519. PubMed ID: 31713476
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of hydroxychloroquine as add-on therapy in uncontrolled type 2 diabetes patients who were using two oral antidiabetic drugs.
    Chakravarti HN, Nag A.
    J Endocrinol Invest; 2021 Mar; 44(3):481-492. PubMed ID: 32594451
    [Abstract] [Full Text] [Related]

  • 3. Safety and effectiveness of insulin detemir in combination with oral antidiabetic agents in an outpatient specialist setting: results of the Italian SOLVE™ observational study.
    Caputo S, Maran A, Mannino D, Morano S, Lastoria G, Nicoziani P.
    Minerva Endocrinol; 2015 Dec; 40(4):249-58. PubMed ID: 26551483
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness, safety, and tolerability of vildagliptin or vildagliptin/metformin combination in patients with type 2 diabetes uncontrolled on insulin therapy in a real-world setting in Egypt: The OMEGA study.
    El Ebrashy I, El Kafrawy N, Raouf R, Yousry D.
    Diabetes Res Clin Pract; 2020 Apr; 162():108042. PubMed ID: 32006641
    [Abstract] [Full Text] [Related]

  • 5. Insulin Detemir in Combination with Oral Antidiabetic Drugs Improves Glycemic Control in Persons with Type 2 Diabetes in Near East Countries: Results from the Lebanese Subgroup.
    Echtay A, Andari E, Atallah P, Moufarrege R, Nemr R.
    Ethn Dis; 2017 Jan 19; 27(1):45-54. PubMed ID: 28115821
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of SGLT2 Inhibitors as the Fifth Drug in the Management of Type 2 Diabetes Mellitus in Asian Indians not Controlled with at least 4 Oral Antidiabetic Drugs.
    Panikar V, Joshi SR, Deogaonkar N, Vadgama J, Nasikkar N, Kamat T, Sheikh S, Jain CC, Wagle T.
    J Assoc Physicians India; 2018 Dec 19; 66(12):46-49. PubMed ID: 31315325
    [Abstract] [Full Text] [Related]

  • 7. Expert Group Consensus Opinion: Role of Anti-inflammatory Agents in the Management of Type-2 Diabetes (T2D).
    Das AK, Kalra S, Tiwaskar M, Bajaj S, Seshadri K, Chowdhury S, Sahay R, Indurkar S, Unnikrishnan AG, Phadke U, Pareek A, Purkait I.
    J Assoc Physicians India; 2019 Dec 19; 67(12):65-74. PubMed ID: 31801334
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, Sitagliptin Study 035 Group.
    Diabetes Obes Metab; 2007 Sep 19; 9(5):733-45. PubMed ID: 17593236
    [Abstract] [Full Text] [Related]

  • 9. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
    Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ, Broedl UC, EMPA-REG PIO™ trial investigators.
    Diabetes Obes Metab; 2014 Feb 19; 16(2):147-58. PubMed ID: 23906415
    [Abstract] [Full Text] [Related]

  • 10. Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin.
    Chamarthi B, Cincotta AH.
    Postgrad Med; 2017 May 19; 129(4):446-455. PubMed ID: 28374645
    [Abstract] [Full Text] [Related]

  • 11. Long-term efficacy of sitagliptin as either monotherapy or add-on therapy to metformin: improvement in glycemic control over 2 years in patients with type 2 diabetes.
    Katzeff HL, Williams-Herman D, Xu L, Golm GT, Wang H, Dong Q, Johnson JR, O'Neill EA, Kaufman KD, Engel SS, Goldstein BJ.
    Curr Med Res Opin; 2015 Jun 19; 31(6):1071-7. PubMed ID: 25850968
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent.
    Tang YZ, Wang G, Jiang ZH, Yan TT, Chen YJ, Yang M, Meng LL, Zhu YJ, Li CG, Li Z, Yu P, Ni CL.
    Diabetol Metab Syndr; 2015 Jun 19; 7():91. PubMed ID: 26500706
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness and Safety of Hydroxychloroquine compared to Teneligliptin in uncontrolled T2DM patients as add-on Therapy.
    Kumar A, Prakash AS.
    J ASEAN Fed Endocr Soc; 2019 Jun 19; 34(1):87-91. PubMed ID: 33442141
    [Abstract] [Full Text] [Related]

  • 14. Comparison of Glycemic Excursion Using Flash Continuous Glucose Monitoring in Patients with Type 2 Diabetes Mellitus Before and After Treatment with Voglibose.
    Kasthuri S, Poongothai S, Anjana RM, Selvakumar J, Muthukumar S, Kayalvizhi S, Tariq S, Honey E, Gupta PK, Venkatesan U, Mohan V.
    Diabetes Technol Ther; 2021 Mar 19; 23(3):213-220. PubMed ID: 32916063
    [Abstract] [Full Text] [Related]

  • 15. A Retrospective Analysis of Fixed Combination of Empagliflozin and Linagliptin in Addition to the Existing Treatment for its Clinical Effectiveness in Adults with Type 2 Diabetes: A Real-World Clinical Experience.
    Gupta A, Malhotra P, Jamwal V, Khalse M.
    J Assoc Physicians India; 2021 Jul 19; 69(7):11-12. PubMed ID: 34431269
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
    Bergenstal R, Lewin A, Bailey T, Chang D, Gylvin T, Roberts V, NovoLog Mix-vs.-Exenatide Study Group.
    Curr Med Res Opin; 2009 Jan 19; 25(1):65-75. PubMed ID: 19210140
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P, Sitagliptin Study 019 Group.
    Clin Ther; 2006 Oct 19; 28(10):1556-68. PubMed ID: 17157112
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effects of Hydroxychloroquine on Progression of Diabetic Retinopathy in Subjects with Rheumatoid Arthritis and Type 2 Diabetes Mellitus.
    Baidya A.
    Curr Diabetes Rev; 2022 Oct 19; 18(9):e180122200322. PubMed ID: 35040415
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.